Tests vemurafenib with metformin in people with advanced melanoma
Tests whether vemurafenib with metformin is safe for adults with advanced melanoma.
Key facts
- Who runs it
- University of Louisville
- Where
- Louisville, United StatesSee the site
- Trial code
- Registry title
- A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 55 people, planned
- Started
- Jul 2012
- Expected to end
- Jun 2027
- Type of study
- Interventional
- Treatments tested
- Vemurafenib
- Metformin
- Record updated
- 29 October 2021
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with melanoma that has the BRAFV600E gene change and has spread or cannot be removed by surgery (Stage IIIC or Stage IV).
- Age
- 18 years or older
- Sex
- Men and women can join.
- Disease stage
- Melanoma confirmed under the microscope, Stage IIIC or Stage IV, with at least 1 site of disease that can be measured on scans (RECIST 1.1). ECOG Performance Status of 0 to 2.
- Earlier treatment
- Must not have had Vemurafenib before. Must not have had melanoma progress while taking Metformin. Radiotherapy for non CNS disease within the 2 weeks before starting is not allowed.
- Biomarker or test result
- BRAFV600E melanoma, confirmed under the microscope.
Main reasons for not taking part
- Prior treatment with Vemurafenib
- Known allergy to Metformin or any of its components
- Melanoma progressed before while on Metformin
- Pregnant or breast-feeding, or refusing contraception or measures to avoid pregnancy
- Any other uncontrolled infection or medical condition that could interfere with the trial
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Male or female patients ≥ 18 years of age
- Patients with histological confirmed BRAFV600E melanoma (Stage IIIC or Stage IV, American Joint Commission on Cancer)
- Eastern Cooperative Oncology Group (ECOG) Performance Status(PS) of 0 to 2
- Life expectancy ≥ 3 months
- At least 1 site of radiographically measurable disease by RECIST 1.1
- Adequate hematologic, renal, and liver function as defined by laboratory values performed within 42 days prior to initiation of dosing:; Absolute neutrophil count (ANC) ≥ 1.0 x 109/L; Platelet count ≥ 50 x 109/L; Hemoglobin ≥ 8 g/dL; Serum creatinine ≤ 2 x upper limit of normal (ULN); Total serum bilirubin ≤ 3 x ULN; Serum aspartate transaminase (AST/SGOT) or serum alanine transaminase (ALT/SGPT) ≤ 3x ULN, and ≤ 4 x ULN if liver metastases are present
- Fertile males should use an effective method of contraception during treatment and for at least 3 months after completion of treatment, as directed by their physician
- Pre-menopausal females and females < 2 years after the onset of menopause should have a negative pregnancy test at Screening. Pre-menopausal females must agree to use an acceptable method of birth control from the time of the negative pregnancy test up to 90 days after the last dose of study drug. Females of non-childbearing potential may be included if they are either surgically sterile or have been postmenopausal for ≥ 1 year
- Before study entry, written informed consent must be obtained from the patient prior to performing any study-related procedures
Who cannot take part
- Prior treatment with Vemurafenib
- Previous progression of melanoma while on Metformin
- Received radiotherapy for non CNS disease within the 2 weeks prior to commencing study treatment or have not recovered from side effects of all radiation-related toxicities to Grade ≤ 1, except for alopecia
- Known hypersensitivity to Metformin or any of its components
- Have any other uncontrolled infection or medical condition that could interfere with the conduct of the study
- Pregnant, breast-feeding, or refusing double barrier contraception, oral contraceptives, or avoidance of pregnancy measures
Where in United States
- James Graham Brown Cancer Center- University of LouisvilleLouisville, United StatesContact: Jason A Chesney, MD PhDTaking people
About the trial
What the trial wants to find out
The main purpose of this study is to evaluate the safety of Vemurafenib in combination with Metformin in melanoma patients. The phase II part of the study will also evaluate the clinical activity of the combined regiment. Based on pre-clinical studies and a phase I trial, the investigators hypothesize that the combination of an FDA-approved non-toxic dose of oral Metformin with Vemurafenib will yield little toxicity and improve clinical outcomes in terms of objective response rates and survival in metastatic melanoma patients.
The group in the trial
- Vemurafenib and MetforminTreatment being tested
Treatment: Vemurafenib and Metformin
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase I/II Trial of Vemurafenib and Metformin to Unresectable Stage IIIC and Stage IV BRAF.V600E+ Melanoma Patients
- Plain-language title
- Tests vemurafenib with metformin in people with advanced melanomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Is it time to test biguanide metformin in the treatment of melanoma?Pigment cell & melanoma research, 2015
- Record updated
- 29 October 2021